Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.

@article{Kunz2006PeptideAW,
  title={Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.},
  author={Christian Kunz and Corina Borghouts and Claudia Buerger and Bernd Groner},
  journal={Molecular cancer research : MCR},
  year={2006},
  volume={4 12},
  pages={983-98}
}
The ErbB2 receptor tyrosine kinase is overexpressed in approximately 30% of breast tumor cases and its overexpression correlates with an unfavorable prognosis. A major contributor for this course of the disease is the insensitivity of these tumors toward chemotherapy. Monoclonal antibodies, inhibiting the ligand-induced activation of the receptor and tyrosine kinase inhibitors acting on the intrinsic enzymatic activity of the intracellular domain, have been developed as targeted drugs. Both… CONTINUE READING
13 Extracted Citations
61 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 13 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 61 references

Regulation of AKT Inhibition and Chemosensitivity

  • S Misra, S Ghatak, A Zoltan-Jones, BP. Toole
  • Mol Cancer Res
  • 2006
1 Excerpt

The neu oncogene: an erb-Brelated gene encoding a 185,000-M r tumour antigen

  • AL Schechter, DF Stern, L Vaidyanathan
  • Nature 1984;312:513–6
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…